SHERMAN JEFFREY W purchased $10K of LRMR

SHERMAN JEFFREY W purchased 3,289 shares of Larimar Therapeutics, Inc. (LRMR) at $3.06 on 2026-11-16.

Original reporting
SEC EDGAR · SHERMAN JEFFREY W
Published Nov 16, 2026, 10:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LRMR
Bullish
high confidence
Mentioned
$LRMR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRMRBullishLow
01

Why it matters

This disclosure adds incremental sentiment information for LRMR but does not include any operational, financial, or regulatory catalyst that would materially reset valuation expectations.

02

Market read

Traders may note the insider buy, but the small size and lack of fundamental catalysts make it unlikely to drive a sustained move.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on prior holdings, intent, or whether other insiders are buying/selling around the same period.

Relevance 4/10Novelty 6/10Timing: filed same day as transaction date, 2026-11-16

Background

The article is an SEC Form 4 insider transaction for Larimar Therapeutics, Inc., showing a director open-market purchase.

Company-level read

Ticker impact

$LRMRBullishHigh confidence
Context

Larimar Therapeutics director Sherman Jeffrey W bought 3,289 shares in an open-market Form 4 on 2026-11-16 for about $10.1k.

Expected impact

Likely limited upside bias as traders may view the purchase as incremental confidence, but impact should be muted given the transaction size.

Evidence & confidence

This is a primary SEC Form 4 disclosure, but the dollar value (~$10k) is small and there is no accompanying guidance, deal, or operational catalyst.

Market effects

No clear sector read-through from a small director purchase.

None.

None.

Counterpoint

The purchase may be routine (compensation-related or personal liquidity timing) and not a strong signal of near-term upside.

Key entities

  • Larimar Therapeutics, Inc.

    LRMR, subject of the Form 4 insider purchase disclosed in the article.

  • Sherman Jeffrey W

    Director who purchased 3,289 shares on 2026-11-16 for $10,057.89.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LRMRMed

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update • Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause o

$LRMRMed

Larimar Therapeutics, Inc. (LRMR): Results of Operations and Financial Condition

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the under

$LRMRMed

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinica

$LRMRMed

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.